Komori
Other Disclosures9987SUZUKEN CO.,LTD.Trading & Wholesale

コラボスクエア and 南江堂 Enter Business Partnership to Jointly Roll Out “メドシルAI,” an AI Knowledge Service for Medical Professionals

コラボスクエア and 南江堂 have entered into a business partnership to jointly promote and enhance 南江堂’s generative AI service for healthcare professionals, “Medsil AI.” コラボスクエア will handle authentication infrastructure, sales and billing, and post-implementation support, while 南江堂 will be responsible for service development and expanding the medical content.

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
450000
people or more (healthcare and care professionals using Collabo ID)
Wording
Definitive
How definitive the wording is.

Announced details

Medsil AI (knowledge AI service for healthcare professionals)Collab IDCollabo Portal (collaboration portal)Medical Care Station (MCS)
Applicable field (uses covered by this announcement)

Healthcare and care settings, including information gathering by physicians, pharmacists, nurses and care professionals; consultations with specialist physicians and pharmacists; learning by junior physicians; and improving the operational efficiency of nurses and medical staff.

Contract Date14 May 2026 (business partnership announced)
What the company reported numerically
Quantitative Effects

The parties state that the service reduces the time required to search for medical information. The amount of time saved is Not disclosed.

Usage history

Collabo ID is used by 450,000 or more healthcare and care professionals.

Relationship between the counterparty and the company
SUZUKEN CO.,LTD.9987
Relationship with the Company

コラボスクエア and 南江堂 have entered into a business partnership. コラボスクエア is a consolidated subsidiary of Suzuken. 南江堂 developed Medsil AI.

Counterparty南江堂

Head office: Bunkyo-ku, Tokyo; Representative Director and President: Kodachi Kenta (小立健太). A publisher engaged in publishing and sales in the medical fields, including medicine, pharmaceuticals and nursing. The company publishes specialist medical books and academic journals and also provides web services with AI-powered search and services integrated with electronic medical records.

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services CoveredMedsil AI (knowledge AI service for healthcare professionals), Collab ID, Collabo Portal (collaboration portal), Medical Care Station (MCS)
Counterparty南江堂
Counterparty overviewHead office: Bunkyo-ku, Tokyo; Representative Director and President: Kodachi Kenta (小立健太). A publisher engaged in publishing and sales in the medical fields, including medicine, pharmaceuticals and nursing. The company publishes specialist medical books and academic journals and also provides web services with AI-powered search and services integrated with electronic medical records.
Relationship with the Companyコラボスクエア and 南江堂 have entered into a business partnership. コラボスクエア is a consolidated subsidiary of Suzuken. 南江堂 developed Medsil AI.
Contract Date14 May 2026 (business partnership announced)
Applicable areaHealthcare and care settings, including information gathering by physicians, pharmacists, nurses and care professionals; consultations with specialist physicians and pharmacists; learning by junior physicians; and improving the operational efficiency of nurses and medical staff.
Quantitative EffectsThe parties state that the service reduces the time required to search for medical information. The amount of time saved is Not disclosed.
Usage historyCollabo ID is used by 450,000 or more healthcare and care professionals.
Items this document does not state (10)
Contract ValueOffering priceLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The importance of faster and more accurate information gathering and greater operational efficiency is increasing in healthcare and care settings. By combining 南江堂’s medical information with the Suzuken Group’s customer network, sales, billing and utilization support, and AI development capabilities, the parties aim to promote the adoption of Medsil AI and improve its quality.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
コラボスクエア and 南江堂 Enter Business Partnership to Jointly Roll Out “メドシルAI,” an AI Knowledge Service for Medical Professionals | SUZUKEN CO.,LTD. (9987) timely disclosure | Komori